JP2025506341A5 - - Google Patents
Info
- Publication number
- JP2025506341A5 JP2025506341A5 JP2024542023A JP2024542023A JP2025506341A5 JP 2025506341 A5 JP2025506341 A5 JP 2025506341A5 JP 2024542023 A JP2024542023 A JP 2024542023A JP 2024542023 A JP2024542023 A JP 2024542023A JP 2025506341 A5 JP2025506341 A5 JP 2025506341A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- ids
- sequence ids
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306434P | 2022-02-03 | 2022-02-03 | |
| US63/306,434 | 2022-02-03 | ||
| US202263370025P | 2022-08-01 | 2022-08-01 | |
| US63/370,025 | 2022-08-01 | ||
| US202263383736P | 2022-11-15 | 2022-11-15 | |
| US63/383,736 | 2022-11-15 | ||
| PCT/US2023/061932 WO2023150677A2 (en) | 2022-02-03 | 2023-02-03 | Anti-cd38 binding molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506341A JP2025506341A (ja) | 2025-03-11 |
| JP2025506341A5 true JP2025506341A5 (enExample) | 2026-02-18 |
Family
ID=87552976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024542023A Pending JP2025506341A (ja) | 2022-02-03 | 2023-02-03 | 抗ｃｄ３８結合分子及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250051473A1 (enExample) |
| EP (1) | EP4473017A4 (enExample) |
| JP (1) | JP2025506341A (enExample) |
| KR (1) | KR20240139079A (enExample) |
| AU (1) | AU2023216348A1 (enExample) |
| CA (1) | CA3240270A1 (enExample) |
| GE (1) | GEAP202416592A (enExample) |
| IL (1) | IL313350A (enExample) |
| MX (1) | MX2024009615A (enExample) |
| WO (1) | WO2023150677A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| WO2026085050A1 (en) | 2024-10-15 | 2026-04-23 | Immunitybio, Inc. | Dual-specific binding molecule useful for isolating specific blood cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA014640B1 (ru) * | 2003-07-21 | 2010-12-30 | Иммьюноджен, Инк. | Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| HK1245171A1 (zh) * | 2014-11-26 | 2018-08-24 | Xencor, Inc. | 结合cd3和cd38的异二聚体抗体 |
| CN117986363A (zh) * | 2016-03-31 | 2024-05-07 | 恩格姆生物制药公司 | 结合蛋白及其使用方法 |
| CA3055790A1 (en) * | 2017-04-07 | 2018-10-11 | Igm Biosciences, Inc. | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| CN110913895B (zh) * | 2017-05-08 | 2024-04-02 | 阿迪马布有限责任公司 | 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法 |
| PE20212262A1 (es) * | 2019-04-17 | 2021-11-29 | Novo Nordisk As | Anticuerpos biespecificos |
| CA3144961A1 (en) * | 2019-07-01 | 2021-01-07 | Sorrento Therapeutics, Inc. | Heterodimeric antibodies that bind to cd38 and cd3 |
| BR112022013071A2 (pt) * | 2020-01-06 | 2022-09-20 | Igm Biosciences Inc | Moléculas de ligação multiméricas altamente sialiladas |
-
2023
- 2023-02-03 JP JP2024542023A patent/JP2025506341A/ja active Pending
- 2023-02-03 GE GEAP202416592A patent/GEAP202416592A/en unknown
- 2023-02-03 CA CA3240270A patent/CA3240270A1/en active Pending
- 2023-02-03 EP EP23750434.5A patent/EP4473017A4/en active Pending
- 2023-02-03 WO PCT/US2023/061932 patent/WO2023150677A2/en not_active Ceased
- 2023-02-03 KR KR1020247028900A patent/KR20240139079A/ko active Pending
- 2023-02-03 US US18/719,191 patent/US20250051473A1/en active Pending
- 2023-02-03 IL IL313350A patent/IL313350A/en unknown
- 2023-02-03 AU AU2023216348A patent/AU2023216348A1/en active Pending
-
2024
- 2024-08-02 MX MX2024009615A patent/MX2024009615A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| TWI743461B (zh) | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 | |
| JP7195929B2 (ja) | 三重特異性および／または三価結合タンパク質 | |
| AU2017216237B2 (en) | PSMA and CD3 bispecific T cell engaging antibody constructs | |
| JP2022545655A5 (enExample) | ||
| US20220289856A1 (en) | Multimeric bispecific anti-cd123 binding molecules and uses thereof | |
| TW201833141A (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| AU2018214223A1 (en) | Low pH pharmaceutical composition comprising T cell engaging antibody constructs | |
| US11932704B2 (en) | Trispecific and/or trivalent binding proteins | |
| US20220119525A1 (en) | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 | |
| JP2023538117A (ja) | 神経免疫疾患のためのｃｄ３／ｃｄ２５抗体 | |
| US20250122299A1 (en) | ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES | |
| IL323855A (en) | Steap2 directed t-cell engagers and compositions thereof | |
| KR20240031229A (ko) | 알파-시누클레인병증 치료용 항체 | |
| JP2024509274A (ja) | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 | |
| JP2025526279A (ja) | 抗ＴＮＦα抗体および組成物 | |
| KR20250148649A (ko) | 항-muc17*cd3*cd28 삼중 특이성 항체 | |
| JP2026500710A (ja) | 二重特異性タンパク質を製造する方法 | |
| KR102240802B1 (ko) | 교차 결합 영역 배향을 갖는 이원 가변 영역 항체-유사 결합 단백질 | |
| CN121219320A (zh) | 针对il12受体的双特异性激动性抗体 | |
| NZ616174B2 (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| HK1194744B (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation |